Stock ATNM ACTINIUM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Actinium Pharmaceuticals, Inc.

Equities

ATNM

US00507W2061

Biotechnology & Medical Research

Market Closed - Nyse
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
6.87 USD +4.73% Intraday chart for Actinium Pharmaceuticals, Inc. +0.29% +35.24%
Apr. 26 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 18 Actinium Pharmaceuticals, Inc. Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 35.86 106 132.4 271.4 139.3 204.6 - -
Enterprise Value (EV) 1 35.86 106 132.4 271.4 139.3 197.4 204.6 204.6
P/E ratio -1.45 x -4.26 x -5.01 x -7.77 x -2.78 x -3.67 x -40 x 5.76 x
Yield - - - - - - - -
Capitalization / Revenue - - 116 x 263 x 1,719 x 1,081 x 2.95 x 1.44 x
EV / Revenue - - 116 x 263 x 1,719 x 1,043 x 2.95 x 1.44 x
EV / EBITDA - -5.06 x -5.42 x -8.12 x -2.72 x -3.26 x 4.42 x 1.03 x
EV / FCF - -4.85 x -6.31 x 32.8 x - -2.59 x -4.44 x -15.6 x
FCF Yield - -20.6% -15.9% 3.05% - -38.6% -22.5% -6.39%
Price to Book - 2.23 x 1.81 x - - -7.39 x -5.68 x -
Nbr of stocks (in thousands) 5,490 13,587 22,031 25,483 27,413 29,783 - -
Reference price 2 6.531 7.800 6.010 10.65 5.080 6.870 6.870 6.870
Announcement Date 5/8/20 3/31/21 3/25/22 3/31/23 3/29/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - 1.144 1.03 0.081 0.1893 69.3 142.4
EBITDA 1 - -20.96 -24.44 -33.4 -51.13 -60.5 46.3 198.7
EBIT 1 -22.07 -22.39 -24.96 -34.1 -51.92 -57.48 -7.702 37.54
Operating Margin - - -2,182.17% -3,311.07% -64,098.77% -30,371% -11.11% 26.36%
Earnings before Tax (EBT) 1 -21.9 -22.22 -24.77 -33.02 -48.82 -59.08 1.142 55.33
Net income 1 -21.9 -22.22 -24.77 -33.02 -48.82 -59.08 -2.149 44.4
Net margin - - -2,165.56% -3,205.53% -60,269.14% -31,218.43% -3.1% 31.18%
EPS 2 -4.500 -1.830 -1.200 -1.370 -1.830 -1.874 -0.1718 1.192
Free Cash Flow 1 - -21.87 -21 8.278 - -76.1 -46.13 -13.08
FCF margin - - -1,835.58% 803.69% - -40,207.12% -66.57% -9.19%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 5/8/20 3/31/21 3/25/22 3/31/23 3/29/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 0.023 0.94 0.045 0.045 - - - - 0.081 - - - - 2.882 41.38
EBITDA 1 -7.911 -5.027 -7.67 -9.578 -11.13 -11.4 -15.43 -14.15 -10.14 -9.381 -14.3 -15.8 -17.4 - -
EBIT 1 -8.048 -5.164 -7.85 -9.799 -11.29 -11.58 -15.64 -14.35 -10.34 -9.597 -15.95 -16.49 -17.06 -17.01 21.08
Operating Margin -34,991.3% -549.36% -17,444.44% -21,775.56% - - - - -12,769.14% - - - - -590.35% 50.93%
Earnings before Tax (EBT) 1 -8.01 -5.129 -7.767 -9.474 -10.65 -11.04 -15.18 -13.28 -9.324 -8.67 -15.78 -16.32 -16.9 -17.01 21.08
Net income 1 -8.01 -5.129 -7.767 -9.474 -10.65 -11.04 -15.18 -13.28 -9.324 -8.67 -15.78 -16.32 -16.9 -17.01 18.11
Net margin -34,826.09% -545.64% -17,260% -21,053.33% - - - - -11,511.11% - - - - -590.35% 43.76%
EPS 2 -0.3600 -0.2300 -0.3300 -0.3800 -0.4300 -0.4300 -0.5800 -0.4900 -0.3300 -0.3100 -0.5467 -0.5400 -0.5367 -0.5000 0.4400
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 3/25/22 5/13/22 8/12/22 11/14/22 3/31/23 5/15/23 8/14/23 11/2/23 3/29/24 4/26/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - - - - - 7.22 - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - -21.9 -21 8.28 - -76.1 -46.1 -13.1
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 - 3.500 3.320 - - -0.9300 -1.210 -
Cash Flow per Share 2 - - - - - -1.540 -0.3800 -
Capex 1 - 0.25 0.13 0.37 - 0.73 0.68 1.85
Capex / Sales - - 11.63% 35.53% - 383.45% 0.98% 1.3%
Announcement Date 5/8/20 3/31/21 3/25/22 3/31/23 3/29/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Actinium Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
6.87 USD
Average target price
25.47 USD
Spread / Average Target
+270.69%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ACTINIUM PHARMACEUTICALS, INC. Stock Actinium Pharmaceuticals, Inc.
+35.24% 202M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ATNM Stock
  4. Financials Actinium Pharmaceuticals, Inc.